-
ASH 2023 | Prof. Fengkui Zhang and Prof. Bing Han Team: KP104 Effectively Controls Intravascular and Extravascular Hemolysis in PNH Patients Without Complement Inhibitor Treatment
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare and life-threatening blood disorder. Due to the complexity of complement biology and various pathogenic pathways, there remains a significant unmet clinical need, urgently requiring next-generation drugs with superior efficacy and dosing convenience compared to current therapies. At the recently held 65th American Society of Hematology (ASH) Annual Meeting,…
-
ASH 2023 | West China Team: Exploration of Blinatumomab and Reduced Dosing of Cyclophosphamide before and after Allogeneic Hematopoietic Stem Cell Transplantation
The 65th American Society of Hematology (ASH) Annual Meeting was held in San Diego, California, from December 9 to 12, 2023. ASH Annual Meeting is the largest and most comprehensive international event covering both basic and clinical research in hematlogy. This year, the Hematology Department at West China Hospital, Sichuan University, presented two oral reports,…
-
ASCO-GU Interview | Dr. Antonio Cigliola: Utility of FDG-PET to predict a pelvic lymph node involvement (LNI) in patients (pts) with MIBC enrolled in neoadjuvant therapy trials.
Editor’s note: Recently, ASCO-GU, the top event in the field of genitourinary cancers, was held in San Francisco, USA. During the meeting, Dr. Antonio Cigliola shared a study on using…
-
Universal Anti-CD7 CAR-T Cells Targeting T-ALL: Functional Analysis and Potential Applications
Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the treatment of hematological malignancies. One of the challenges in CAR-T cell therapy is the limited availability of target antigens that…
-
Quizartinib Plus Chemotherapy in Newly Diagnosed Patients with FLT3-internal-tandem-duplication-positive Acute Myeloid Leukemia: A Phase 3 Trial
Acute myeloid leukemia (AML) is a genetically heterogeneous disease associated with poor clinical outcomes. Mutations in FMS-related receptor tyrosine kinase 3 (FLT3) are common in AML, with FLT3-internal-tandem-duplication (ITD) mutations…
-
Current status of diagnosis and treatment of chronic lymphocytic leukemia in China: A nationalmulticenter survey research
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are mature lymphocyte clonal proliferative tumors that primarily occurs in the middle-aged and elderly population and exhibits specific immunophenotypic characteristics. It is characterized by the abnormal proliferation…
-
Efficacy and safety of mitoxantrone hydrochloride liposome injection in treatment of peripheral T-celllymphomas: a multicenter, non-interventional, ambispective cohort, real-world study (MOMENT)
This study is a real-world research with a ambispective cohort (MOMENT study), including clinical data from 198 patients who received mitoxantrone hydrochloride liposome injection as monotherapy or combination therapy at…
-
Shanghai Institute of Hematology’s Team Led by Academician SaijuanChenand Chief Physician Jianqing Mi Unveils Temporal Characteristics of Cytokine Release and Molecular Mechanisms of CAR-T Re-expansion in Cell Immunotherapy
In January 2024, the team led by Academician Saijuan Chen and Chief Physician Jianqing Mi at the Shanghai Institute of Hematology published a research paper in the journal “Nature Communications.” The…
Connecting Medical Expertise through Media